United Therapeutics Corporation (UTHR)
UTHRNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$588.80
+7.11 (+1.22%) today
At the close, Nov 10, 3:59 PM ET. After hours $588.61 –
- Market cap
- $25.12bn
- P/E
- 22.2
- EPS, last 4 quarters
- $26.50
- Dividend yield
- –
- Day range
- $577.26 to $593.10
- 52-week range
- $445.81 to $614.23
- Average volume
- 772.1k
- Previous close
- $581.70
Analysts
13 coveringBuy10 buy, 2 hold, 1 sell
Targets a year out average $682.71, +15.9% from here
Earnings
next estimate $5.88Next report
Dec 2025
+13.6%
Mar 2026
-13.5%
Jun 2026
+6.6%
Sep 2026
-2.4%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $790.20m | $781.50m | $783.30m | $832.50m |
| Gross profit | $686.80m | $648.10m | $683.80m | $733.40m |
| Operating income | $356.70m | $325.80m | $330.80m | $307.80m |
| Net income | $364.30m | $274.90m | $333.00m | $258.60m |
Last four quarters: revenue $3.19bn, margin 38.6%, free cash flow $867.20m
News
8 latest- What United Therapeutics (UTHR) Said on Its Q3 Earnings CallMarketBeat · 6 days ago
- United Therapeutics (UTHR) Q3 2026 Earnings Call TranscriptThe Motley Fool · 6 days ago
- United Therapeutics (UTHR) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks · 6 days ago
- United Therapeutics Corp Reports Drop In Q3 Profit RTTNews · 6 days ago
- United Therapeutics (UTHR) Q3 Earnings Miss EstimatesZacks · 6 days ago
- State Street SPDR S&P Biotech ETF Experiences Big OutflowBNK Invest · Nov 2, 2026
- Notable Friday Option Activity: CRCL, ALAB, UTHRBNK Invest · Oct 30, 2026
- SGIOY vs. UTHR: Which Stock Is the Better Value Option?Zacks · Oct 30, 2026
The company
Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- unither.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.